Clinical implications of mutational analysis in gastrointestinal stromal tumours

被引:0
作者
A Hoeben
P Schöffski
M Debiec-Rychter
机构
[1] University Hospitals Leuven,Department of General Medical Oncology and Laboratory of Experimental Oncology
[2] Leuven Cancer Institute,undefined
[3] Catholic University of Leuven,undefined
[4] Center for Human Genetics,undefined
[5] Catholic University of Leuven,undefined
来源
British Journal of Cancer | 2008年 / 98卷
关键词
gastrointestinal stromal tumours; mutational analysis; targeted therapy; imatinib mesylate;
D O I
暂无
中图分类号
学科分类号
摘要
The management of localised and advanced gastrointestinal stromal tumours (GISTs) in terms of histological diagnosis, surgery, imaging, medical treatment and molecular biology has rapidly changed since introduction of imatinib mesylate for molecularly targeted therapy in 2000. In this minireview, we briefly summarise and discuss the current data relevant to the increasing role of molecular characterisation of GISTs in the diagnosis, risk assessment and effective targeted therapy.
引用
收藏
页码:684 / 688
页数:4
相关论文
共 360 条
  • [1] Andersson J(2006)Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis Gastroenterology 130 1573-1581
  • [2] Bumming P(2005)Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 4182-4190
  • [3] Meis-Kindblom JM(2004)Gene expression in gatrointestinal stromal tumors is distinguished by Clin Cancer Res 10 3282-3290
  • [4] Sihto H(2006) genotype and anatomic site Cancer Res 66 9153-9161
  • [5] Nupponen N(2004)Heat-shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor J Clin Oncol 22 3813-3825
  • [6] Joensuu H(2005)Biology of gastrointestinal stromal tumors J Clin Oncol 23 5357-5364
  • [7] Odén A(2005)A mutations in gastrointestinal stromal tumors: frequency, spectrum and Gastroenterology 128 270-279
  • [8] Gustavsson B(2006) sensitivity to imatinib Eur J Cancer 42 1093-1103
  • [9] Kindblom LG(2002)Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants Hum Pathol 33 466-477
  • [10] Nilsson B(2007)KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours J Natl Compr Canc Netw 5 S1-S2